Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines
- PMID: 9607841
- DOI: 10.1086/515298
Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines
Abstract
Relative avidity of IgG to Streptococcus pneumoniae type 6B and 23F polysaccharides (PSs) was measured in sera of children immunized with pneumococcal vaccines, using an EIA and the chaotropic agent thiocyanate. Infants were immunized at 2, 4, and 6 months of age with pneumococcal PS-diphtheria toxoid conjugate vaccine, and boosted at 14 months with the homologous conjugate or a pneumococcal PS vaccine. The concentrations of antibodies to 6B and 23F PSs increased significantly after the booster with both vaccines. A significant increase in the avidity of anti-6B and anti-23F antibodies was seen after the booster with conjugate but not with PS vaccine. Avidity also increased in another group of infants primed and boosted with pneumococcal PS-meningococcal protein conjugate but not in a group boosted with PS vaccine after priming with pneumococcal PS-tetanus toxoid conjugate. In the latter group, however, the avidity of anti-6B was high before boosting.
Similar articles
-
Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood.Vaccine. 1999 Apr 9;17(15-16):1970-7. doi: 10.1016/s0264-410x(98)00458-7. Vaccine. 1999. PMID: 10217596 Clinical Trial.
-
Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.J Infect Dis. 2001 Nov 1;184(9):1211-5. doi: 10.1086/323648. Epub 2001 Sep 25. J Infect Dis. 2001. PMID: 11598848 Clinical Trial.
-
Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid.Vaccine. 2000 Jan 18;18(13):1218-26. doi: 10.1016/s0264-410x(99)00393-x. Vaccine. 2000. PMID: 10649623 Clinical Trial.
-
Immunogenicity of pneumococcal conjugate vaccines.Pediatr Infect Dis J. 2000 Apr;19(4):388-93. doi: 10.1097/00006454-200004000-00035. Pediatr Infect Dis J. 2000. PMID: 10783041 Review.
-
Current status and prospects for some improved and new bacterial vaccines.Annu Rev Public Health. 1986;7:105-25. doi: 10.1146/annurev.pu.07.050186.000541. Annu Rev Public Health. 1986. PMID: 3521639 Review. No abstract available.
Cited by
-
Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.Clin Vaccine Immunol. 2007 Feb;14(2):139-45. doi: 10.1128/CVI.00336-06. Epub 2006 Dec 13. Clin Vaccine Immunol. 2007. PMID: 17167035 Free PMC article.
-
Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A.Immunol Res. 2014 Jan;58(1):75-85. doi: 10.1007/s12026-013-8427-6. Immunol Res. 2014. PMID: 23660844
-
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.Infect Immun. 2007 Apr;75(4):1794-800. doi: 10.1128/IAI.01673-06. Epub 2007 Jan 29. Infect Immun. 2007. PMID: 17261612 Free PMC article. Clinical Trial.
-
Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.Infect Immun. 1999 May;67(5):2366-70. doi: 10.1128/IAI.67.5.2366-2370.1999. Infect Immun. 1999. PMID: 10225896 Free PMC article.
-
Correlation of pneumococcal antibody concentration and avidity with patient clinical and immunologic characteristics.J Clin Immunol. 2013 May;33(4):847-56. doi: 10.1007/s10875-013-9870-9. Epub 2013 Feb 3. J Clin Immunol. 2013. PMID: 23378166
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
